Medicines and Healthcare products Regulatory Agency gov.uk

IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review

Imported from official source

October 20, 2026 09:01 Alert

Safety Classified by Officially

Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation has been withdrawn. Healthcare professionals should no longer prescribe or administer the IXCHIQ vaccine and should instead consider alternative measures to reduce the risk of chikungunya infection in individuals travelling to affected areas.

the UK marketing authorisation for the IXCHIQ vaccine (chikungunya vaccine) has been withdrawn and the product is being removed from the UK market

do not prescribe, supply or administer the IXCHIQ vaccine, and dispose of any remaining stock in accordance with local policies

ensure that any materials, systems or communications referring to available UK vaccination options are updated to remove the IXCHIQ vaccine

advise travellers of alternative measures to prevent chikungunya infection, including other available vaccines for chikungunya, avoidance of mosquito bites and adherence to current health-related travel advice

patients who have previously received the IXCHIQ vaccine do not need to take any specific action as a result of this regulatory decision. However, they should seek medical advice if they have experienced a suspected adverse reaction following IXCHIQ vaccination

continue to report suspected adverse reactions associated with the IXCHIQ vaccine on a Yellow Card

Advice for Healthcare Professionals to Provide to Patients:

following a review of all available evidence the MHRA has withdrawn the UK marketing authorisation for the IXCHIQ vaccine because the benefits of this vaccine are no longer considered to outweigh its risks

individuals who have already received the IXCHIQ vaccine do not need another vaccination or any other specific medical treatment because of this decision

anyone who experiences a suspected side effect following vaccination should seek medical advice and report it on a Yellow Card

This is an extract. The publication continues at the source.

Contains public sector information licensed under the Open Government Licence v3.0. Licence

Read the original at the source: https://www.gov.uk/drug-safety-update/ixchiq-chikungunya-vaccine-uk-marketing-authorisation-withdrawn-following-safety-review

Officially imported this from Medicines and Healthcare products Regulatory Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization: Medicines and Healthcare products Regulatory Agency — imported from official source
Official source: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency.atom ATOM
Imported: October 20, 2026 10:01
Versions: 1 recorded
Identity: https://www.gov.uk/drug-safety-update/ixchiq-chikungunya-vaccine-uk-marketing-authorisa...